Small, fast, and accurate, the cobas® Liat® System is an innovation in point-of-care testing, providing laboratory-quality results for some of the most common infections in 20 minutes or less.

Take aim at tuberculosis. The leading killer of HIV-positive people, Roche is committed to working towards the WHO road map to stop this challenging infection.

Global Access Program - COVID-19 - Combating the global COVID-19 pandemic

Learn how you can benefit from an automation system that meets your needs and processes more samples in less time.

Roche has partnered with (RED) on a shared mission to bring awareness to the importance of diagnostics and testing in the global fight against HIV/AIDS through educational creative content.

With more than 1 million sexually transmitted infections acquired every day, advanced diagnostic testing strategies are essential to reducing the global burden of disease as well as ensuring sexual and reproductive health.

The most frequent adverse event in healthcare delivery is a direct result of medical advancement. Could further progress be the answer?

Screening is an essential part of protecting the most vulnerable. Congenital infections can have a devastating impact, but early testing, preventive measures and treatment options make it possible to prevent many of them. Screening has a key role.

Roche today announced that its cobas® SARS-CoV-2 Test for use on the widely available, high-throughput cobas® 6800/8800 Systems has received Emergency Use Authorisation (EUA) from the U.S. Food and Drug Administration (FDA) for testing individuals without symptoms or reasons to suspect COVID-19.

The Open Environment allows software developers to easily integrate their image analysis tools for tumour tissue with Roche uPath enterprise software.

Roche press release: Roche receives FDA approval for first companion diagnostic to identify dMMR solid tumour patients eligible for anti-PD-1 immunotherapy.

cobas® 6800/8800 Systems are included as part of the updated World Health Organization (WHO) policy guidelines on nucleic acid amplification tests (NAATs) to detect tuberculosis (TB) and drug-resistant TB. The new guidance expands the number of rapid molecular tests available to national TB programmes in high-burden countries, enabling multi-partner diagnostic approaches that can benefit patients and communities.

Roche receives FDA approval for first companion diagnostic to identify endometrial cancer patients eligible for anti-PD1 immunotherapy.

Since the first EU Quality Management System certificate (IVDR) was issued by our notified body, TÜV SÜD, in December 2020, all relevant Quality Management Systems have been successfully audited.

Roche launches DISCOVERY Green HRP chromogen detection kit to expand immunohistochemistry multiplexing in cancer research